The Cost Effectiveness of Endoscopic Ultrasound ( EUS ) Based Strategy in Diagnosis of Common Bile Duct Stones
The Cost Effectiveness Between EUS-based Strategy Versus Endoscopic Retrograde Cholangiopancreatography ( ERCP )-Based Strategy in Diagnosis of Common Bile Duct Stones in Patients With Intermediate Risk: a Study in Developing Country.
研究概览
详细说明
Background: Multiple reports showed the efficacy of EUS comparable to ERCP in the diagnosis of CBD stone. The EUS-based strategy has provided the cost saving in diagnosis of CBD stone in patients with intermediate risk in previous studies in western population. There were multiple parameters involved the cost effectiveness analysis included cost of ERCP, cost of EUS, prevalence of CBD stones, the sensitivity and specificity of EUS and the rate of complications related to EUS and ERCP. These parameter may vary from center to center and from region to region.
Aims: To assess the cost effectiveness of EUS based strategy versus ERCP based strategy in diagnosis of CBD stones in patients with intermediate risk in a developing country.
Method : A prospective study in 141 patients with suspected CBD stones based on clinical, biochemical and imaging by trans-abdominal ultrasonography or computed abdominal tomography. All patients underwent EUS. All patients with high risk for CBD stone underwent ERCP after the EUS. For patients with intermediate risk for CBD stone, ERCP's were done at the discretion of the attending physicians. For patients with ERCP done, the diagnosis of CBD stone was confirmed by ERCP demonstration of CBD stone. In patients with intermediate risk without ERCP done, clinical follow up to assess biliary symptoms and liver function test as surrogated markers for CBD stone at 3 months interval for one year were done. The false negative rate in patients with EUS and ERCP done in this study was used to estimate the false negative rate in patients in clinical surrogated group.
Definition: High risk of CBD stones was defined when CBD stone was detected by US/CT or dilated duct with abnormal liver function test ( LFT ). Intermediate risk of CBD stones was defined when US/CT showed normal bile duct with abnormal LFT or dilated duct with normal LFT.
Cost analysis :The cost of making diagnosis of CBD stone excluding all costs of treatment was analyzed. The cost of all patients with suspected CBD stones undergoing ERCP was calculated and compared with the strategy of EUS follow by ERCP. The cost was evaluated by (1) mean costs of EUS and ERCP based on the actual cost in our center which included costs of medical staffs, disposable materials, drugs, equipment amortization and maintenance. (2) cost associated with complications induced by the procedure.
Statistical analysis: Test performance of the endoscopic ultrasound in diagnosis of CBD stones was analyzed with two by two tables. The sensitivity, specificity, positive and negative predictive values were calculated.
研究类型
注册 (实际的)
联系人和位置
学习地点
-
-
Songkhla
-
Hatyai、Songkhla、泰国、90110
- NKC Institues of Gastroenterology and Hepatology, Prince of Songkla University
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
描述
Inclusion Criteria:
- history of biliary pain or recent cholangitis
- acute pancreatitis
- abnormal liver function test
- dilatation of CBD and or CBD stone detected by trans-abdominal ultrasound and or computed tomography.
Exclusion Criteria:
- unstable hemodynamics
- severe coagulopathy
- refusal to participate
学习计划
研究是如何设计的?
设计细节
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
High risk group
High risk group was defined when CBD stones was detected by ultrasound ( US ) / computed tomography ( CT ) or dilated duct with abnormal LFT.
|
Patients with high risk underwent EUS examination under conscious sedation.
EUS was examined from second part of duodenum up to duodenal bulb.
All patients even if negative EUS examination of CBD stone were underwent ERCP in the same session.
The ERCPs were performed in standard manner.
All patients were contacted by phone on day 1, 3 and 30 after the procedure.
其他名称:
|
|
Intermediate risk group
Intermediate risk group was defined when US/CT showed normal bile duct with abnormal LFT or dilated duct with normal LFT.
|
Patients with intermediate risk underwent EUS examination under conscious sedation.
EUS was examined from second part of duodenum up to duodenal bulb.
ERCPs were done at the discretion of the attending physicians.
The ERCPs were performed in standard manner.
The patients without ERCP done were contacted at 3 months interval to assess symptoms and LFT for 12 months.
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
The cost of making diagnosis of CBD stone
大体时间:within 12 months after EUS
|
The cost of making diagnosis of CBD stone will be measured as the difference in the cost of all patients undergoing ERCP and ERCP follow by EUS intervention.
The cost was evaluated by (1) mean costs of EUS and ERCP based on the actual cost in our center which included costs of medical staffs, disposable materials, drugs, equipment amortization and maintenance.
(2) costs associated with complications induced by the procedure.
|
within 12 months after EUS
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
The accuracy of EUS in diagnosis of CBD stone
大体时间:within 12 months after EUS
|
This will be measured as proportion of patients who encounter a correctly diagnosis of CBD stone by EUS.
Positive EUS finding was confirmed by ERCP.
Negative EUS finding was confirmed by ERCP or absence of symptoms for 12 months.
|
within 12 months after EUS
|
|
The safety of EUS and ERCP procedure
大体时间:within 1 months
|
This will be measured as proportion of patients who encounter a procedural complication (%) during EUS and ERCP that includes pancreatitis, perforation or hemorrhage
|
within 1 months
|
合作者和调查者
调查人员
- 研究主任:Bancha Ovartlarnporn, MD、NKC Institue of Gastroenterology and Hepatology, Faculty of Medicine, Prince of Songkla University, Hatyai, Songkla, Thailand.
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.